Feasibility of electronic brachytherapy in cervix cancer–A dosimetric comparison of different brachytherapy techniques

Lozares-Cordero, Sergio (Universidad de Zaragoza) ; González Pérez, Victor ; Pellejero-Pellejero, Santiago ; Rodríguez Ruiz, Lucia ; Guinot Rodríguez, José Luis ; Villafranca-Iturre, Elena ; Méndez-Villamón, Agustina (Universidad de Zaragoza) ; Gandía Martínez, Almudena ; Fuentemilla-Urío, Naiara ; Ruggeri, Ricardo

Resumen: Introducción: This study analyzes cases in which electronic brachytherapy (eBT) led to acceptable treatment plans in cervical cancer. Findings were compared with dosimetry values obtained in 192 Ir-based treatments according to the high-risk clinical target volume (HR-CTV) and the disease stage.

Material and methods: We retrospectively analyzed 48 patients with cervical cancer from two centers. The patients were treated with 192 Ir based on MRI. It was possible to use interstitial needles via an Utrecht-type applicator. Dosimetry was simulated using eBT and the parameters D90 and D98 (HR-CTV) and D2cc, D1cc, and D0.1cc (bladder, rectum, and sigmoid colon) were evaluated. The Mann-Whitney U test was used for comparison. The overall cohort of patients was analyzed, as were the sub-cohorts based on stage (FIGO stages I + IIA, IIB and III–IV). Finally, the dosimetry of the eBT plans was evaluated, and the plans obtained were classified as “good”, “acceptable”, or “poor”.

Results: Statistically significant differences were found between the eBT and 192 Ir plans for D98 (HR-CTV), D1cc and D0.1cc (bladder), and D1cc and D0.1cc (sigmoid colon). A total of 31 cases (64.6%) were considered good, seven (14.6%) were considered acceptable, and 10 (20.8%) were considered poor. For volumes < 30 cc, all the plans were good or acceptable; for volumes > 30 cc, 54.3% were good, and 71.4% were good or acceptable. By stage, eBT plans for patients with stage IB–IIA disease were good in 100%, whereas those for patients with stage IIB were good in 70.6% and III–IV disease were good in 50%.

Conclusions: eBT provides appropriate dosimetry for treatment of cervical cancer in selected cases.

Idioma: Inglés

DOI: 10.1016/j.brachy.2022.01.006

Año: 2022

Publicado en: Brachytherapy 21, 4 (2022), 389-396
ISSN: 1538-4721

Factor impacto JCR: 1.9 (2022)

Categ. JCR: RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING rank: 100 / 135 = 0.741 (2022) - Q3 - T3
Categ. JCR: ONCOLOGY rank: 215 / 241 = 0.892 (2022) - Q4 - T3

Factor impacto CITESCORE: 3.6 - Medicine (Q2)

Factor impacto SCIMAGO: 0.741 - Radiology, Nuclear Medicine and Imaging (Q2) - Oncology (Q2)

Tipo y forma: Article (Published version)

Área (Departamento): Área Radiol. y Medicina Física (Dpto. Microb.Ped.Radio.Sal.Pú.)